Intestinal marginal zone B-cell lymphoma of MALT type: Clinical manifestation and outcome of a rare disease

Sung Yong Oh; Hyuk Chan Kwon; Won Seog Kim; In Gyu Hwang; Yeon Hee Park; Kihyun Kim; Young Hae Ko; Baek Yeol Ryoo; Hye Jin Kang; Eunmi Nam; Jae Hoon Lee; Jung Han Kim; Hyo Jin Kim

doi:10.1111/j.1600-0609.2007.00925.x

Intestinal marginal zone B-cell lymphoma of MALT type: Clinical manifestation and outcome of a rare disease

Sung Yong Oh, Hyuk Chan Kwon, Won Seog Kim, In Gyu Hwang, Yeon Hee Park, Kihyun Kim, Young Hae Ko, Baek Yeol Ryoo, Hye Jin Kang, Eunmi Nam, Jae Hoon Lee, Jung Han Kim, Hyo Jin Kim

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

Intestinal marginal zone B-cell lymphoma of the MALT type (I-MZL) is a relatively uncommon form of lymphoma. Twenty-seven patients with histologically-confirmed I-MZL were analyzed. The patients initially presented with abdominal pain (62.9%), and diarrhea (22.2%). The most common involved site was the ileo-caecal area (40.7%). Musshoff's stage I_E, II _E1, II_E2, III_E and IV were present in 44%, 15%, 11%, 7.4% and 22% respectively. Sixty-three percent were in the low-risk group according to the Follicular Lymphoma International Prognostic Index. Complete response and partial response were achieved in 82% and 4% patients. The estimated 5-year overall survival (OS) and progression-free survival (PFS) rates were 86% and 54%. Stage ≥ II_E2 was determined to be a poor prognostic factor for PFS and OS. I-MZL commonly manifests in an early-stage, low-risk state and tends to respond well to local and systemic treatment with favorable prognosis. I-MZL tends to be an indolent disease - characterized by prolonged survival with frequent relapses, similarly to other site MZLs.

Original language	English
Pages (from-to)	287-291
Number of pages	5
Journal	European Journal of Haematology
Volume	79
Issue number	4
DOIs	https://doi.org/10.1111/j.1600-0609.2007.00925.x
State	Published - Oct 2007

Keywords

Intestinal
Marginal zone B-cell lymphoma of MALT type

Access to Document

10.1111/j.1600-0609.2007.00925.x

Cite this

@article{f7a93180c1f54fbc8841b6293fcddb31,

title = "Intestinal marginal zone B-cell lymphoma of MALT type: Clinical manifestation and outcome of a rare disease",

abstract = "Intestinal marginal zone B-cell lymphoma of the MALT type (I-MZL) is a relatively uncommon form of lymphoma. Twenty-seven patients with histologically-confirmed I-MZL were analyzed. The patients initially presented with abdominal pain (62.9%), and diarrhea (22.2%). The most common involved site was the ileo-caecal area (40.7%). Musshoff's stage IE, II E1, IIE2, IIIE and IV were present in 44%, 15%, 11%, 7.4% and 22% respectively. Sixty-three percent were in the low-risk group according to the Follicular Lymphoma International Prognostic Index. Complete response and partial response were achieved in 82% and 4% patients. The estimated 5-year overall survival (OS) and progression-free survival (PFS) rates were 86% and 54%. Stage ≥ IIE2 was determined to be a poor prognostic factor for PFS and OS. I-MZL commonly manifests in an early-stage, low-risk state and tends to respond well to local and systemic treatment with favorable prognosis. I-MZL tends to be an indolent disease - characterized by prolonged survival with frequent relapses, similarly to other site MZLs.",

keywords = "Intestinal, Marginal zone B-cell lymphoma of MALT type",

author = "Oh, {Sung Yong} and Kwon, {Hyuk Chan} and Kim, {Won Seog} and Hwang, {In Gyu} and Park, {Yeon Hee} and Kihyun Kim and Ko, {Young Hae} and Ryoo, {Baek Yeol} and Kang, {Hye Jin} and Eunmi Nam and Lee, {Jae Hoon} and Kim, {Jung Han} and Kim, {Hyo Jin}",

year = "2007",

month = oct,

doi = "10.1111/j.1600-0609.2007.00925.x",

language = "English",

volume = "79",

pages = "287--291",

journal = "European Journal of Haematology",

issn = "0902-4441",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "4",

}

TY - JOUR

T1 - Intestinal marginal zone B-cell lymphoma of MALT type

T2 - Clinical manifestation and outcome of a rare disease

AU - Oh, Sung Yong

AU - Kwon, Hyuk Chan

AU - Kim, Won Seog

AU - Hwang, In Gyu

AU - Park, Yeon Hee

AU - Kim, Kihyun

AU - Ko, Young Hae

AU - Ryoo, Baek Yeol

AU - Kang, Hye Jin

AU - Nam, Eunmi

AU - Lee, Jae Hoon

AU - Kim, Jung Han

AU - Kim, Hyo Jin

PY - 2007/10

Y1 - 2007/10

N2 - Intestinal marginal zone B-cell lymphoma of the MALT type (I-MZL) is a relatively uncommon form of lymphoma. Twenty-seven patients with histologically-confirmed I-MZL were analyzed. The patients initially presented with abdominal pain (62.9%), and diarrhea (22.2%). The most common involved site was the ileo-caecal area (40.7%). Musshoff's stage IE, II E1, IIE2, IIIE and IV were present in 44%, 15%, 11%, 7.4% and 22% respectively. Sixty-three percent were in the low-risk group according to the Follicular Lymphoma International Prognostic Index. Complete response and partial response were achieved in 82% and 4% patients. The estimated 5-year overall survival (OS) and progression-free survival (PFS) rates were 86% and 54%. Stage ≥ IIE2 was determined to be a poor prognostic factor for PFS and OS. I-MZL commonly manifests in an early-stage, low-risk state and tends to respond well to local and systemic treatment with favorable prognosis. I-MZL tends to be an indolent disease - characterized by prolonged survival with frequent relapses, similarly to other site MZLs.

AB - Intestinal marginal zone B-cell lymphoma of the MALT type (I-MZL) is a relatively uncommon form of lymphoma. Twenty-seven patients with histologically-confirmed I-MZL were analyzed. The patients initially presented with abdominal pain (62.9%), and diarrhea (22.2%). The most common involved site was the ileo-caecal area (40.7%). Musshoff's stage IE, II E1, IIE2, IIIE and IV were present in 44%, 15%, 11%, 7.4% and 22% respectively. Sixty-three percent were in the low-risk group according to the Follicular Lymphoma International Prognostic Index. Complete response and partial response were achieved in 82% and 4% patients. The estimated 5-year overall survival (OS) and progression-free survival (PFS) rates were 86% and 54%. Stage ≥ IIE2 was determined to be a poor prognostic factor for PFS and OS. I-MZL commonly manifests in an early-stage, low-risk state and tends to respond well to local and systemic treatment with favorable prognosis. I-MZL tends to be an indolent disease - characterized by prolonged survival with frequent relapses, similarly to other site MZLs.

KW - Intestinal

KW - Marginal zone B-cell lymphoma of MALT type

UR - http://www.scopus.com/inward/record.url?scp=34548546481&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0609.2007.00925.x

DO - 10.1111/j.1600-0609.2007.00925.x

M3 - Article

C2 - 17692101

AN - SCOPUS:34548546481

SN - 0902-4441

VL - 79

SP - 287

EP - 291

JO - European Journal of Haematology

JF - European Journal of Haematology

IS - 4

ER -

Intestinal marginal zone B-cell lymphoma of MALT type: Clinical manifestation and outcome of a rare disease

Abstract

Keywords

Access to Document

Fingerprint

Cite this